CD8A and melanoma: While this drug has not yet entered clinical trials this strategy might be an appealing way to minimize the associated risks of a systemic STING agonist treatment.[63] Furthermore, SR‐717 demonstrated anti‐tumor activity in a melanoma mouse model after intraperitoneal (IP) delivery leading to increased CD8+ T cell and NK cell numbers in tumor‐draining lymph nodes as well as the spleen.[65] The expression of CD107a as a marker for CD8+ T cell degranulation and NK cell activity was upregulated in both cell types within the tumor and spleen.